← All trials
NCT07246707
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Jun 30, 2028
- First posted
- Nov 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOfficial
- TScan Therapeutics, Inc.Collaborator
- Zhejiang UniversitySponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.